文献速递心脑血管急症消化、代谢与肾脏急症

烟酸在管理心血管疾病结局中的作用评估:系统评价与荟萃分析

Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Netw Open · 2019-04-05
一句话结论荟萃分析显示烟酸在二级预防中总体无预防关联,单药治疗在未用他汀者中与部分心血管事件减少相关,但证据主要来自20世纪70–80年代的老试验。

该系统评价与荟萃分析检索MEDLINE、Embase、Cochrane Central、ClinicalTrials.gov及TrialResults-center(建库至2017年10月),纳入以烟酸治疗心血管疾病的临床试验,荟萃分析纳入报告烟酸暴露与至少1项长期心血管结局的随机临床试验。119项临床试验中17项记录烟酸对至少1项心血管结局的影响,荟萃分析纳入35 760例有心血管疾病或血脂异常病史的患者。累积证据未发现烟酸在二级预防中与心血管结局存在预防关联;分层荟萃分析显示,未接受他汀治疗者中烟酸单药治疗与部分心血管事件减少相关(急性冠脉综合征:相对危险度0.74,95%CI 0.58–0.96;卒中:相对危险度0.74,95%CI 0.59–0.94;血运重建:相对危险度0.51,95%CI 0.37–0.72),这些结果主要来自20世纪70年代和80年代开展的2项试验。作者认为烟酸作为单药可能在二级预防的血脂控制中有一定用途,或许用于对他汀不耐受的患者,但证据来自较老的试验,其人群可能不能代表当前患者。

要点

  • 荟萃分析纳入35 760例有心血管疾病或血脂异常病史的患者,累积证据未发现烟酸在二级预防中与心血管结局存在预防关联。
  • 未接受他汀治疗者中,烟酸单药治疗与急性冠脉综合征减少相关(相对危险度0.74,95%CI 0.58–0.96)。
  • 未接受他汀治疗者中,烟酸单药治疗与卒中减少相关(相对危险度0.74,95%CI 0.59–0.94)。
  • 未接受他汀治疗者中,烟酸单药治疗与血运重建减少相关(相对危险度0.51,95%CI 0.37–0.72)。
  • 上述单药治疗结果主要来自20世纪70年代和80年代开展的2项试验,其人群可能不能代表当前患者。

适用人群与场景

  • 荟萃分析纳入35 760例有心血管疾病或血脂异常病史的患者。
  • 系统评价纳入以烟酸作为心血管疾病治疗的临床试验。
  • 分层分析中与部分心血管事件减少相关的结果来自未接受他汀治疗的患者。

研究设计与关键结果

  • 研究类型为系统评价与荟萃分析,检索MEDLINE、Embase、Cochrane Controlled Clinical Trial Register(Central)、ClinicalTrials.gov及TrialResults-center,建库至2017年10月。
  • 119项临床试验中17项记录烟酸对至少1项心血管结局的影响;荟萃分析纳入报告烟酸暴露与至少1项长期心血管结局的随机临床试验,共35 760例有心血管疾病或血脂异常病史的患者。
  • 累积证据未发现烟酸在二级预防中与心血管结局存在预防关联。
  • 分层荟萃分析显示,未接受他汀治疗者中烟酸单药治疗与急性冠脉综合征减少相关(相对危险度0.74,95%CI 0.58–0.96)。
  • 未接受他汀治疗者中烟酸单药治疗与卒中减少相关(相对危险度0.74,95%CI 0.59–0.94)。
  • 未接受他汀治疗者中烟酸单药治疗与血运重建减少相关(相对危险度0.51,95%CI 0.37–0.72)。
  • 上述结果主要来自20世纪70年代和80年代开展的2项试验。

证据类型、等级与局限

  • 证据类型为系统评价与荟萃分析,采用逆方差加权法和随机效应模型合并风险比,并用随机效应加权荟萃回归分析高密度脂蛋白胆固醇水平变化与合并结果对数风险比的关联。
  • 局限:作者指出这些结果主要来自20世纪70年代和80年代开展的2项试验,证据来自较老的试验,其人群可能不能代表当前患者。

对床旁实践的改变

  • 作者认为烟酸作为单药可能在二级预防的血脂控制中有一定用途,或许用于对他汀不耐受的患者。
  • 作者指出证据来自较老的试验,其人群可能不能代表当前患者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Niacin remains a therapeutic option for patients with cardiovascular disease, but recent studies have called into question the effectiveness of other drugs that increase high-density lipoprotein cholesterol levels.

OBJECTIVE: To systematically review and evaluate the evidence supporting current US Food and Drug Administration-approved uses of niacin in cardiovascular disease prevention settings.

DATA SOURCES: MEDLINE, Embase, Cochrane Controlled Clinical Trial Register (Central), ClinicalTrials.gov, and TrialResults-center, from database inception to October 2017.

STUDY SELECTION: The systematic review included clinical trials involving niacin as a treatment for cardiovascular disease. The meta-analysis included randomized clinical trials reporting niacin's effect, as exposure, on at least 1 long-term cardiovascular disease outcome.

DATA EXTRACTION AND SYNTHESIS: Aggregate study-level data were extracted between November 2017 and January 2018 by 3 independent reviewers, and the analysis was performed in February 2018. Inverse-variance weighted methods were used to produce pooled risk ratios using random-effects models for between-study heterogeneity. Random effects-weighted metaregression analysis was used to assess the association of change in high-density lipoprotein cholesterol levels with the log risk ratio of the pooled results.

MAIN OUTCOMES AND MEASURES: Cardiovascular disease, coronary heart disease mortality, and other cardiovascular events, including acute coronary syndrome, fatal and nonfatal stroke, revascularization, and major adverse cardiac events.

RESULTS: Of 119 clinical trials, 17 documented niacin's effect on at least 1 cardiovascular disease outcome. The meta-analysis included 35 760 patients with histories of cardiovascular disease or dyslipidemia. Cumulative evidence found no preventive association of niacin with cardiovascular outcomes in secondary prevention. Stratified meta-analysis showed an association of niacin monotherapy with reduction of some cardiovascular events among patients without statin treatment (acute coronary syndrome: relative risk, 0.74; 95% CI, 0.58-0.96; stroke: relative risk, 0.74; 95% CI, 0.59-0.94; revascularization: relative risk, 0.51; 95% CI, 0.37-0.72). These results were mainly derived from 2 trials conducted in the 1970s and 1980s.

CONCLUSIONS AND RELEVANCE: Niacin may have some use in lipid control for secondary prevention as monotherapy, perhaps in patients intolerant to statins, but evidence is from older studies on a population potentially not representative of current-day patients.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. D'Andrea E, Hey SP, Ramirez CL, et al. Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis. JAMA Netw Open. 2019. PMID: 30977858. doi:10.1001/jamanetworkopen.2019.2224

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。